Effects of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy.
3. RATIONALE FOR BF2.649 IN NARCOLEPSY Narcolepsy is a disabling syndrome affecting the generation and organizations of sleep and wakefulness, first described by Westphal and Gelineau in 19th century. Excessive Daytime Sleepiness (EDS) and cataplexy are two main symptoms of narcolepsy. Other symptoms referred to as auxiliary symptoms are hypnagogic and hypnopompic hallucinations, sleep paralysis, dyssomnia and automatic behaviour. The prevalence of narcolepsy is estimated around 25 per 100 000 in Causasian population. It is often extremely incapacitating, interfering with every aspect of life, in work and social settings.
Several breakthroughs in the understanding of physiopathology of narcolepsy have recently shown that most narcoleptic patients display a strongly decreased CSF level of orexins, a group of hypothalamic peptides with wake-promoting activity. It was also found that sporadic narcolepsy in dogs, mice and humans may also be related to a deficiency in the production of orexin ligands. Narcolepsy may be a neurodegenerative or autoimmune disorder resulting in a loss of hypothalamic neurons containing the orexin [Baumann CR & Bassetti CL Lancet Neurol. 2005 ; Dauvilliers Y et al, Clin Neurophysiol. 2003 ].
In accordance with guidelines published by the European task force [Billiard M et al, Eur J Neurol. 2006] , management of narcolepsy with or without cataplexy relies on several classes of drugs, namely stimulants for EDS, antidepressants for cataplexy and hypnosedative drugs for disturbed nocturnal sleep. The first line pharmacological treatment of EDS and irresistible episodes of sleep rely on Modafinil, 100-400 mg/day, given in two doses, one in the morning and one early in the afternoon, the need for amphetamines and amphetamine-like stimulants (e.g. methylphenidate) has been decreased. Sodium oxybate and antidepressants are main drug therapies of cataplexy.
BF2.649, an H3R inverse agonist promotes significantly vigilance in mice knock out for the orexin gene, a reliable model of narcolepsy, whereas the animals remain calm, a difference with treatment by amphetamine-like drugs which induce psychomotor excitation. In addition, BF2.649 shows a significant inhibitory effect on the occurrence of narcolepsy episodes during the dark period. These narcolepsy episodes are to be compared to cataplexy episodes in human [Chemelli et al., Cell 1999] 11. In agreement, Modafinil, in humans, does not show any effects on cataplexy, even if it improves wakefulness by an ill-defined mechanism. Thus anticataplectic drugs, such as antidepressants, are given in addition to Modafinil to narcoleptic patients.
Taken together, the preclinical and clinical results provide a compelling rationale for this study to verify and confirm, under randomized double-blind and placebo-controlled conditions, the safety and efficacy of escalating dose of BF2.649 in the treatment of EDS and cataplexy in narcolepsy.
It is on the basis of preclinical studies, and on the observation of the first included patients, that the doses to be administered were determined.
Treatment of Excessive Daytime Sleepiness in Narcolepsy.
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
|Official Title:||Randomized, Double-blind, Placebo and Comparator-controlled, Parallel-group, Multi-center Trial Assessing the Effects of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy|
- Epworth Sleepiness Scale scores (ESS) [ Time Frame: 10 weeks ] [ Designated as safety issue: No ]
The primary efficacy endpoint is Epworth Sleepiness Scale scores (ESS) change between the BF2.649-treatment group, the placebo-group, and the Modafinil-treatment group during an 8-week treatment period.
The ESS is a self-administered questionnaire to the patients to evaluate their chances of dozing in height different situations often encountered in the daily life.
The average of ESS performed at V6 and V7 will be compared to the average of ESS performed at V2 and V3.
- patient sleep diary [ Time Frame: 10 weeks ] [ Designated as safety issue: No ]
Following secondary outcome measures will be reported in the patient sleep diary:
- Number and duration of diurnal involuntary sleep attacks and episodes of severe sleepiness
- Number of cataplexy total and partial.
- Number of hallucinations.
- Number of sleep paralysis.
- Number and duration of nocturnal awakening and total duration of nocturnal sleep time.
- Maintenance of Wakefulness Test (MWT) [ Time Frame: 10 weeks ] [ Designated as safety issue: No ]The Maintenance of Wakefulness Test (MWT) is used in this study to assess an individual's ability to maintain awake while resisting the pressure to fall asleep. Patients will be administrated four 40-minute MWT sessions at 2 hours interval at inclusion visit (V3) and at endpoint visit (V7 or the last on-study visit), according to validated standard [Doghramji K et al, Electroencephalogr Clin Neurophysiol. 1997] . The changes in MWT will be compared between the treatment groups. The MWT will be renewed at V7 only for patients who had a MWT <11 at V3.
- Test of Sustained Attention to Response Task (SART) [ Time Frame: 10 weeks ] [ Designated as safety issue: No ]The Test of Sustained Attention to Response Task (SART) has been used for the quantification of vigilance and attention in narcolepsy patients [Fronczek R et al, Sleep 2006] . The SART will be performed at inclusion visit (V3) and at endpoint (V7 or the last on-study visit for prematurely withdrawn patients). The changes in SART will be compared between the treatment groups.
- Clinical Global Impressions of Change [ Time Frame: 10 weeks ] [ Designated as safety issue: No ]The severities of EDS and of cataplexy will be measured at baseline by the investigator using the Clinical Global Impression of Severity (CGI-S) in order to describe the population. At each follow-up visit, the patients' change in EDS and in cataplexy compared to baseline will be rated by the same investigator using Clinical Global Impression of Change (CGI-C) to document the perceived change in patients' illness.
- European Quality of life questionnaire (EQ-5D) [ Time Frame: 10 weeks ] [ Designated as safety issue: No ]EQ-5D is a reliable and validated measure of quality of life. Narcolepsy has a clear negative effect on this outcome measure [Dodel R. et al, Sleep Med. 2007] . EQ-5D will be completed at baseline visit (V2), inclusion visit (V3), stable-dose visit (V5), endpoint visit (V7) and withdrawal visit (V8). The changes between treatment groups will be analysed as an evaluation of the illness evolution.
- Patient's Global Opinion on the effect of treatment [ Time Frame: 10 weeks ] [ Designated as safety issue: No ]At each visit under treatment (V4, V5, V6, V7 and V8 or last on-study visit), patients evaluate the Global effect of their treatment by comparing the period prior to that visit with the patient's prestudy condition.
|Study Start Date:||November 2010|
|Study Completion Date:||July 2012|
|Primary Completion Date:||April 2012 (Final data collection date for primary outcome measure)|
BF2.649 (pitolisant) is a novel, highly potent, selective, orally active histamine H3 receptor antagonist/inverse agonist (Ki of 0.3 nM) at the human receptor.
BF2.649 is provided in capsules. One-quarter or one-half of BF2.649 tablet at 20 mg (corresponding to 5-, and 10 mg, respectively).
Patients should take 2 capsules per day with a glass of water. They will be instructed to take 1 capsule in the morning (after waking up, before breakfast around 8.00 a.m.) and 1 capsule at noon.
Other Name: Pitolisant
Active Comparator: Vigil
Therapeutic indications Narcolepsy with and without cataplexy. Moderate to severe obstructive sleep apnoea syndrome with excessive daytime sleepiness despite adequate CPAP therapy.
Moderate to severe chronic shift work sleep disorder with excessive sleepiness in patients who work rotating night shifts, if other sleep hygiene measures did not lead to a satisfactory improvement.
Modafinil is provided in capsules. The capsules are identical in appearance to ensure that neither the patient nor the investigator nor members of the clinical staff knows the identity of the study medication.
Modafinil tablet at 100 mg are enclosed in gelatine capsules. Patients should take 2 capsules per day with a glass of water. They will be instructed to take 1 capsule in the morning (after waking up, before breakfast around 8.00 a.m.) and 1 capsule at noon.
Other Name: Modafinil
|Placebo Comparator: Placebo||
placebo is provided in capsules. The capsules are identical in appearance to ensure that neither the patient nor the investigator nor members of the clinical staff knows the identity of the study medication.
placebo consist of identical capsules containing lactose only. Patients should take 2 capsules per day with a glass of water. They will be instructed to take 1 capsule in the morning (after waking up, before breakfast around 8.00 a.m.) and 1 capsule at noon.
Other Name: Placebo
Please refer to this study by its ClinicalTrials.gov identifier: NCT01638403
|Evelyne DESCHAMPS DE PAILLETTE|
|Paris, France, 75002|
|Study Chair:||DAUVILLIERS Yves||Hôpital Gui de Chauliac - 80, avenue A. Fliche , 34295 Montpellier cedex 5 - FRANCE|